Metformin × glycemic control

TrialPloS one2015

The study to understand the genetics of the acute response to metformin and glipizide in humans (SUGAR-MGH): design of a pharmacogenetic resource for type 2 diabetes.

Geoffrey A Walford et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 1,000 people · 2015

Randomised comparison

Raised glycemic control

+0.64+0.33 to +0.95

As reported

difference 0.64, 95% CI 0.33–0.95

Range includes no effect

No clear effect on glycemic control

−0.85−43.8 to +26.7

As reported

difference −0.85, 95% CI −43.8 to 26.7

Not counted

Raised glycemic control

+20.3+12.5 to +28.0

As reported

difference 20.3, 95% CI 12.5–28.0

Not counted

Raised glycemic control

+0.43+0.23 to +0.64

As reported

difference 0.43, 95% CI 0.23–0.64

+3 more in the walkthrough ↓

Seven numbers in the abstract

the abstract, start to end

absence of metformin; paired difference 20.3 [95% CI 12.5, 28.0]; P<0.0001).

± 126.2 min*mmol/L; paired difference -0.85 [95% CI -43.8, 26.7]; P = 0.63

mmol/L respectively; group difference 0.43 [95% CI 0.23, 0.64]; P<0.0001),

vs. 5.85 ± 1.48 mmol/L; group difference -0.81 [95% CI -1.18, -0.45], P<0.0001

4.89 ± 0.61 mmol/L; paired difference 0.58 [95% CI 0.44, 0.73], P<0.0001;

± 150.9 min*mmol/L; group difference 156.8 [95% CI 94.0, 219.7]; P =

mmol/L respectively; group difference 0.64 [95% CI 0.33, 0.95]; P<0.0001),

← favours treatmentfavours comparator →
could be chance
Glycemic control
20.312.5–28.0
Glycemic control
−0.85−43.8 to 26.7
Glycemic control
0.430.23–0.64
Glycemic control
−0.81−1.18 to −0.45
Glycemic control
0.580.44–0.73
Glycemic control
156.894.0–220
Glycemic control
0.640.33–0.95
MetforminSulfonylureas & glinidesInsulinGlycemic control
1 / 4

16 papers cite it

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
this paperpooled itcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 25812009